At Ananda we are focused on developing essentially THC-free cannabidiol (CBD) formulations to treat complex, chronic inflammatory pain conditions.

In the UK alone, 28 million people grapple with chronic pain, often facing inadequate, expensive and invasive treatments. With the NHS spending over £5 billion annually on musculoskeletal pain alone and with the global anti-inflammatory drugs market projected to reach US$191.42 billion by 2027, Ananda is poised to make a significant impact.

Backed by an increasingly robust body of clinical and real-world evidence, including a >250 page NICE evidence review and call for research, we believe in the potential of CBD to transform the treatment landscape for chronic pain.

We are committed to deliver:
• The highest quality medicines, manufactured in the UK according to the strictest pharmaceutical standards
• Robust clinical trial evidence by partnering with world-leading researchers
• CBD medicines that are available on the NHS.

Our dynamic team boasts expertise in chronic pain and inflammation research, cannabis science, pharmaceutical R&D and equity capital markets. Collaborating with globally respected scientists, we are determined to deliver on our goals.